ID   HLAF_HUMAN              Reviewed;         346 AA.
AC   P30511; Q5JQI8; Q5JQJ1; Q5SPT5; Q860R0; Q8MGQ1; Q8WLP5; Q95HC0; Q9TP68;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   07-APR-2021, entry version 187.
DE   RecName: Full=HLA class I histocompatibility antigen, alpha chain F;
DE   AltName: Full=CDA12;
DE   AltName: Full=HLA F antigen;
DE   AltName: Full=Leukocyte antigen F {ECO:0000303|PubMed:1688605};
DE   AltName: Full=MHC class I antigen F;
DE   Flags: Precursor;
GN   Name=HLA-F {ECO:0000303|PubMed:1688605, ECO:0000303|PubMed:1707659,
GN   ECO:0000312|HGNC:HGNC:4963};
GN   Synonyms=HLA-5.4 {ECO:0000303|PubMed:1688605, ECO:0000303|PubMed:1707659},
GN   HLAF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND
RP   VARIANT SER-272.
RX   PubMed=1688605; DOI=10.1084/jem.171.1.1;
RA   Geraghty D.E., Wei X., Orr H.T., Koller B.H.;
RT   "Human leukocyte antigen F (HLA-F). An expressed HLA gene composed of a
RT   class I coding sequence linked to a novel transcribed repetitive element.";
RL   J. Exp. Med. 171:1-18(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND
RP   VARIANT SER-272.
RX   PubMed=1707659; DOI=10.1093/intimm/2.6.531;
RA   Lury D., Epstein H., Holmes N.;
RT   "The human class I MHC gene HLA-F is expressed in lymphocytes.";
RL   Int. Immunol. 2:531-537(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND
RP   VARIANT SER-272.
RX   PubMed=10727083; DOI=10.3109/10425179909033955;
RA   Hampe A., Coriton O., Andrieux N., Carn G., Lepourcelet M., Mottier S.,
RA   Dreano S., Gatius M.T., Hitte C., Soriano N., Galibert F.;
RT   "A 356-Kb sequence of the subtelomeric part of the MHC class I region.";
RL   DNA Seq. 10:263-299(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT SER-272.
RX   PubMed=14705989; DOI=10.1111/j.1399-0039.2004.00145.x;
RA   He X., Xu L., Liu Y., Zeng Y.;
RT   "Identification of a novel HLA-F allele - HLA-F*010102.";
RL   Tissue Antigens 63:181-183(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND
RP   VARIANT SER-272.
RX   PubMed=16570139; DOI=10.1007/s00251-005-0076-z;
RA   Pyo C.W., Williams L.M., Moore Y., Hyodo H., Li S.S., Zhao L.P.,
RA   Sageshima N., Ishitani A., Geraghty D.E.;
RT   "HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype
RT   structure and variation spanning the nonclassical class I genes.";
RL   Immunogenetics 58:241-251(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-272.
RA   Gharwan H., Sageshima N., Ishitani A., Geraghty D.E.;
RT   "A comparative study of the MHC-F expression patterns between humans and
RT   nonhuman primates.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-272.
RA   Shiina S., Tamiya G., Oka A., Inoko H.;
RT   "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-272.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   SER-272.
RC   TISSUE=Lung, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   SUBUNIT, INTERACTION WITH LILRB1 AND LILRB2, AND TISSUE SPECIFICITY.
RX   PubMed=11169396;
RX   DOI=10.1002/1521-4141(200012)30:12<3552::aid-immu3552>3.0.co;2-l;
RA   Lepin E.J., Bastin J.M., Allan D.S., Roncador G., Braud V.M., Mason D.Y.,
RA   van der Merwe P.A., McMichael A.J., Bell J.I., Powis S.H.,
RA   O'Callaghan C.A.;
RT   "Functional characterization of HLA-F and binding of HLA-F tetramers to
RT   ILT2 and ILT4 receptors.";
RL   Eur. J. Immunol. 30:3552-3561(2000).
RN   [12]
RP   SUBUNIT, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, GLYCOSYLATION,
RP   INTERACTION WITH TAP1, INTERACTION WITH TAP2, INTERACTION WITH CALR, AND
RP   INTERACTION WITH B2M.
RX   PubMed=10605026; DOI=10.4049/jimmunol.164.1.319;
RA   Wainwright S.D., Biro P.A., Holmes C.H.;
RT   "HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib
RT   protein with a restricted expression pattern.";
RL   J. Immunol. 164:319-328(2000).
RN   [13]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF VAL-346, MUTAGENESIS OF
RP   336-ARG--ARG-338, SUBUNIT, AND MOTIF.
RX   PubMed=16709803; DOI=10.4049/jimmunol.176.11.6464;
RA   Boyle L.H., Gillingham A.K., Munro S., Trowsdale J.;
RT   "Selective export of HLA-F by its cytoplasmic tail.";
RL   J. Immunol. 176:6464-6472(2006).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=20865824; DOI=10.1002/eji.201040348;
RA   Lee N., Ishitani A., Geraghty D.E.;
RT   "HLA-F is a surface marker on activated lymphocytes.";
RL   Eur. J. Immunol. 40:2308-2318(2010).
RN   [15]
RP   SUBUNIT, AND INTERACTION WITH HLA-E.
RX   PubMed=20483783; DOI=10.4049/jimmunol.1000078;
RA   Goodridge J.P., Burian A., Lee N., Geraghty D.E.;
RT   "HLA-F complex without peptide binds to MHC class I protein in the open
RT   conformer form.";
RL   J. Immunol. 184:6199-6208(2010).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23851683; DOI=10.4049/jimmunol.1300080;
RA   Goodridge J.P., Lee N., Burian A., Pyo C.W., Tykodi S.S., Warren E.H.,
RA   Yee C., Riddell S.R., Geraghty D.E.;
RT   "HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-
RT   presentation pathway.";
RL   J. Immunol. 191:1567-1577(2013).
RN   [17]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KIR3DL2, AND INTERACTION WITH KIR2DS4.
RX   PubMed=24018270; DOI=10.4049/jimmunol.1300081;
RA   Goodridge J.P., Burian A., Lee N., Geraghty D.E.;
RT   "HLA-F and MHC class I open conformers are ligands for NK cell Ig-like
RT   receptors.";
RL   J. Immunol. 191:3553-3562(2013).
RN   [18]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KIR3DS1, TISSUE SPECIFICITY, INDUCTION
RP   BY HIV-1 INFECTION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=27455421; DOI=10.1038/ni.3513;
RA   Garcia-Beltran W.F., Hoelzemer A., Martrus G., Chung A.W., Pacheco Y.,
RA   Simoneau C.R., Rucevic M., Lamothe-Molina P.A., Pertel T., Kim T.E.,
RA   Dugan H., Alter G., Dechanet-Merville J., Jost S., Carrington M.,
RA   Altfeld M.;
RT   "Open conformers of HLA-F are high-affinity ligands of the activating NK-
RT   cell receptor KIR3DS1.";
RL   Nat. Immunol. 17:1067-1074(2016).
RN   [19]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=26928464; DOI=10.1038/nm.4052;
RA   Song S., Miranda C.J., Braun L., Meyer K., Frakes A.E., Ferraiuolo L.,
RA   Likhite S., Bevan A.K., Foust K.D., McConnell M.J., Walker C.M.,
RA   Kaspar B.K.;
RT   "Major histocompatibility complex class I molecules protect motor neurons
RT   from astrocyte-induced toxicity in amyotrophic lateral sclerosis.";
RL   Nat. Med. 22:397-403(2016).
RN   [20]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=28185362; DOI=10.1111/aji.12643;
RA   Hackmon R., Pinnaduwage L., Zhang J., Lye S.J., Geraghty D.E., Dunk C.E.;
RT   "Definitive class I human leukocyte antigen expression in gestational
RT   placentation: HLA-F, HLA-E, HLA-C, and HLA-G in extravillous trophoblast
RT   invasion on placentation, pregnancy, and parturition.";
RL   Am. J. Reprod. Immunol. 77:0-0(2017).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 22-305 IN COMPLEX WITH
RP   SELF-PEPTIDE, DISULFIDE BOND, FUNCTION, SUBUNIT, INTERACTION WITH LILRB1,
RP   INTERACTION WITH KIR3DS1 AND KIR3DL2, AND MUTAGENESIS OF TRP-83.
RX   PubMed=28636952; DOI=10.1016/j.immuni.2017.06.002;
RA   Dulberger C.L., McMurtrey C.P., Holzemer A., Neu K.E., Liu V.,
RA   Steinbach A.M., Garcia-Beltran W.F., Sulak M., Jabri B., Lynch V.J.,
RA   Altfeld M., Hildebrand W.H., Adams E.J.;
RT   "Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through
RT   Interactions with NK Cell Receptors.";
RL   Immunity 46:1018-1029(2017).
CC   -!- FUNCTION: Non-classical major histocompatibility class Ib molecule
CC       postulated to play a role in immune surveillance, immune tolerance and
CC       inflammation. Functions in two forms, as a heterotrimeric complex with
CC       B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as
CC       an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In
CC       complex with B2M, presents non-canonical self-peptides carrying post-
CC       translational modifications, particularly phosphorylated self-peptides.
CC       Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory
CC       receptor, a major player in maternal-fetal tolerance. Peptide-free OC
CC       acts as a ligand for KIR3DS1 and KIR3DL2 receptors (PubMed:28636952).
CC       Upon interaction with activating KIR3DS1 receptor on NK cells, triggers
CC       NK cell degranulation and anti-viral cytokine production
CC       (PubMed:27455421). Through interaction with KIR3DL2 receptor, inhibits
CC       NK and T cell effector functions (PubMed:24018270). May interact with
CC       other MHC class I OCs to cross-present exogenous viral, tumor or minor
CC       histompatibility antigens to cytotoxic CD8+ T cells, triggering
CC       effector and memory responses (PubMed:23851683). May play a role in
CC       inflammatory responses in the peripheral nervous system. Through
CC       interaction with KIR3DL2, may protect motor neurons from astrocyte-
CC       induced toxicity (PubMed:26928464). {ECO:0000269|PubMed:23851683,
CC       ECO:0000269|PubMed:24018270, ECO:0000269|PubMed:26928464,
CC       ECO:0000269|PubMed:27455421, ECO:0000269|PubMed:28636952}.
CC   -!- SUBUNIT: Forms a heterotrimer with B2M and a self-peptide
CC       (PubMed:28636952). Binds a diverse number of peptides ranging from 7 to
CC       more than 30 amino acids (PubMed:28636952). Peptide-bound HLA-F-B2M
CC       interacts with LILRB1 and LILRB2 but not with KIR3DS1 or KIR3DL2; this
CC       interaction is direct (PubMed:28636952, PubMed:11169396). The OC form
CC       interacts with KIR3DS1, KIR2DS4 and KIR3DL2; this interaction is direct
CC       (PubMed:28636952, PubMed:27455421, PubMed:24018270). Interacts with
CC       TAP1-TAP2 complex and CALR; this interaction is required for
CC       appropriate folding and peptide loading (PubMed:10605026,
CC       PubMed:11169396). Interacts with the coat protein complex II and 14-3-3
CC       proteins; these interactions likely control the anterograde ER-to-Golgi
CC       transport of HLA-F (PubMed:16709803). HLA-F-B2M complex interacts with
CC       the heavy chain of other MHC class I molecules including HLA-A and HLA-
CC       E; this interaction may regulate the intracellular trafficking and the
CC       stability of peptide-free MHC class I OCs (PubMed:20483783).
CC       {ECO:0000269|PubMed:10605026, ECO:0000269|PubMed:11169396,
CC       ECO:0000269|PubMed:16709803, ECO:0000269|PubMed:20483783,
CC       ECO:0000269|PubMed:24018270, ECO:0000269|PubMed:27455421,
CC       ECO:0000269|PubMed:28636952}.
CC   -!- INTERACTION:
CC       P30511; P13747: HLA-E; NbExp=2; IntAct=EBI-2811134, EBI-726583;
CC       P30511; P43632: KIR2DS4; NbExp=4; IntAct=EBI-2811134, EBI-13916812;
CC       P30511; P43629: KIR3DL1; NbExp=4; IntAct=EBI-2811134, EBI-3910993;
CC       P30511; P43630: KIR3DL2; NbExp=6; IntAct=EBI-2811134, EBI-6165894;
CC       P30511; Q14943: KIR3DS1; NbExp=6; IntAct=EBI-2811134, EBI-15316524;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16709803,
CC       ECO:0000269|PubMed:23851683, ECO:0000305|PubMed:27455421}; Single-pass
CC       type I membrane protein. Early endosome membrane
CC       {ECO:0000269|PubMed:23851683}. Lysosome membrane
CC       {ECO:0000269|PubMed:23851683}. Note=For cross-presentation transits
CC       from the cell surface through endosomal pathway to lysosomes, where the
CC       peptide is generated from internalized exogenous antigen.
CC       {ECO:0000269|PubMed:23851683}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P30511-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30511-2; Sequence=VSP_038846;
CC       Name=3;
CC         IsoId=P30511-3; Sequence=VSP_040349;
CC   -!- TISSUE SPECIFICITY: Expressed in resting B cells (at protein level).
CC       Expressed in secondary lymphoid organs rich in B and T cells such as
CC       the tonsils, spleen, and thymus (at protein level) (PubMed:10605026,
CC       PubMed:11169396). Expressed in the endothelial cells of the tonsils
CC       (PubMed:11169396). Expressed on activated lymphoid cells including B
CC       cells, NK cells, CD4+ T cells and memory T cells (at protein level)
CC       (PubMed:27455421, PubMed:20865824). Expressed in motor neurons of
CC       spinal cord (PubMed:26928464). {ECO:0000269|PubMed:10605026,
CC       ECO:0000269|PubMed:11169396, ECO:0000269|PubMed:20865824,
CC       ECO:0000269|PubMed:26928464, ECO:0000269|PubMed:27455421}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal liver (at protein level)
CC       (PubMed:10605026). Expressed in placenta villous mesenchyme,
CC       cytotrophoblast, syncytiotrophoblast and invasive extravillous
CC       trophoblast (at protein level) (PubMed:28185362).
CC       {ECO:0000269|PubMed:10605026, ECO:0000269|PubMed:28185362}.
CC   -!- INDUCTION: Up-regulated in CD4+ T cells upon stimulation via TCR and
CC       upon HIV-1 infection. {ECO:0000269|PubMed:27455421}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10605026,
CC       ECO:0000269|PubMed:27455421}.
CC   -!- SIMILARITY: Belongs to the MHC class I family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC24827.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAH09260.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB63337.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAA34947.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAB46623.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X17093; CAA34947.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF055066; AAC24827.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AY253269; AAO86773.1; -; mRNA.
DR   EMBL; AY253270; AAO86774.1; -; mRNA.
DR   EMBL; AY253271; AAO86775.1; -; mRNA.
DR   EMBL; AF523284; AAM74979.1; -; Genomic_DNA.
DR   EMBL; AF523285; AAM74980.1; -; Genomic_DNA.
DR   EMBL; AF523286; AAM74981.1; -; Genomic_DNA.
DR   EMBL; AF523287; AAM74982.1; -; Genomic_DNA.
DR   EMBL; AF523288; AAM74983.1; -; Genomic_DNA.
DR   EMBL; AF523289; AAM74984.1; -; Genomic_DNA.
DR   EMBL; AF523290; AAM74985.1; -; Genomic_DNA.
DR   EMBL; AF523291; AAM74986.1; -; Genomic_DNA.
DR   EMBL; AF523292; AAM74987.1; -; Genomic_DNA.
DR   EMBL; AF523293; AAM74988.1; -; Genomic_DNA.
DR   EMBL; AF523294; AAM74989.1; -; Genomic_DNA.
DR   EMBL; AF523295; AAM74990.1; -; Genomic_DNA.
DR   EMBL; AF523296; AAM74991.1; -; Genomic_DNA.
DR   EMBL; AF523297; AAM74992.1; -; Genomic_DNA.
DR   EMBL; AY645742; AAT73225.1; -; Genomic_DNA.
DR   EMBL; AY645743; AAT73226.1; -; Genomic_DNA.
DR   EMBL; AY645744; AAT73227.1; -; Genomic_DNA.
DR   EMBL; AY645745; AAT73228.1; -; Genomic_DNA.
DR   EMBL; AY645746; AAT73229.1; -; Genomic_DNA.
DR   EMBL; AY645748; AAT73231.1; -; Genomic_DNA.
DR   EMBL; AY645749; AAT73232.1; -; Genomic_DNA.
DR   EMBL; AY645750; AAT73233.1; -; Genomic_DNA.
DR   EMBL; AY645751; AAT73234.1; -; Genomic_DNA.
DR   EMBL; AY645752; AAT73235.1; -; Genomic_DNA.
DR   EMBL; AY645753; AAT73236.1; -; Genomic_DNA.
DR   EMBL; AY645754; AAT73237.1; -; Genomic_DNA.
DR   EMBL; AY645756; AAT73239.1; -; Genomic_DNA.
DR   EMBL; AY645757; AAT73240.1; -; Genomic_DNA.
DR   EMBL; AY645758; AAT73241.1; -; Genomic_DNA.
DR   EMBL; AY645759; AAT73242.1; -; Genomic_DNA.
DR   EMBL; DQ367723; ABD38924.1; -; mRNA.
DR   EMBL; BA000025; BAB63337.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL022723; CAB46623.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL645939; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL669813; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL844851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX005428; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR753818; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX927250; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03223.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03226.1; -; Genomic_DNA.
DR   EMBL; BC009260; AAH09260.2; ALT_INIT; mRNA.
DR   EMBL; BC062991; AAH62991.1; -; mRNA.
DR   CCDS; CCDS43437.1; -. [P30511-3]
DR   CCDS; CCDS43438.1; -. [P30511-1]
DR   CCDS; CCDS43439.1; -. [P30511-2]
DR   PIR; A60384; A60384.
DR   RefSeq; NP_001091948.1; NM_001098478.1. [P30511-2]
DR   RefSeq; NP_001091949.1; NM_001098479.1. [P30511-3]
DR   RefSeq; NP_061823.2; NM_018950.2. [P30511-1]
DR   PDB; 5IUE; X-ray; 2.62 A; A/E/G/I=22-305.
DR   PDB; 5KNM; X-ray; 3.30 A; A=22-305.
DR   PDBsum; 5IUE; -.
DR   PDBsum; 5KNM; -.
DR   SMR; P30511; -.
DR   BioGRID; 109379; 22.
DR   IntAct; P30511; 19.
DR   MINT; P30511; -.
DR   STRING; 9606.ENSP00000259951; -.
DR   GlyGen; P30511; 1 site.
DR   iPTMnet; P30511; -.
DR   PhosphoSitePlus; P30511; -.
DR   BioMuta; HLA-F; -.
DR   DMDM; 317373438; -.
DR   EPD; P30511; -.
DR   jPOST; P30511; -.
DR   MassIVE; P30511; -.
DR   PaxDb; P30511; -.
DR   PeptideAtlas; P30511; -.
DR   PRIDE; P30511; -.
DR   ProteomicsDB; 54704; -. [P30511-1]
DR   ProteomicsDB; 54705; -. [P30511-2]
DR   ProteomicsDB; 54706; -. [P30511-3]
DR   Antibodypedia; 26089; 191 antibodies.
DR   DNASU; 3134; -.
DR   Ensembl; ENST00000259951; ENSP00000259951; ENSG00000204642. [P30511-3]
DR   Ensembl; ENST00000334668; ENSP00000334263; ENSG00000204642. [P30511-1]
DR   Ensembl; ENST00000359076; ENSP00000351977; ENSG00000206509. [P30511-2]
DR   Ensembl; ENST00000376848; ENSP00000366044; ENSG00000229698. [P30511-2]
DR   Ensembl; ENST00000376861; ENSP00000366057; ENSG00000204642. [P30511-1]
DR   Ensembl; ENST00000383515; ENSP00000373007; ENSG00000137403. [P30511-2]
DR   Ensembl; ENST00000420067; ENSP00000393535; ENSG00000235220. [P30511-2]
DR   Ensembl; ENST00000434407; ENSP00000397376; ENSG00000204642. [P30511-2]
DR   Ensembl; ENST00000440590; ENSP00000399835; ENSG00000237508. [P30511-2]
DR   GeneID; 3134; -.
DR   KEGG; hsa:3134; -.
DR   UCSC; uc003nnm.5; human. [P30511-1]
DR   CTD; 3134; -.
DR   DisGeNET; 3134; -.
DR   GeneCards; HLA-F; -.
DR   HGNC; HGNC:4963; HLA-F.
DR   HPA; ENSG00000204642; Low tissue specificity.
DR   MIM; 143110; gene.
DR   neXtProt; NX_P30511; -.
DR   OpenTargets; ENSG00000204642; -.
DR   PharmGKB; PA35082; -.
DR   VEuPathDB; HostDB:ENSG00000204642.13; -.
DR   eggNOG; ENOG502RQEK; Eukaryota.
DR   GeneTree; ENSGT00980000198488; -.
DR   HOGENOM; CLU_047501_1_1_1; -.
DR   InParanoid; P30511; -.
DR   OMA; QYWEWTT; -.
DR   PhylomeDB; P30511; -.
DR   TreeFam; TF336617; -.
DR   PathwayCommons; P30511; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   SIGNOR; P30511; -.
DR   BioGRID-ORCS; 3134; 7 hits in 985 CRISPR screens.
DR   ChiTaRS; HLA-F; human.
DR   GeneWiki; HLA-F; -.
DR   GenomeRNAi; 3134; -.
DR   Pharos; P30511; Tbio.
DR   PRO; PR:P30511; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P30511; protein.
DR   Bgee; ENSG00000204642; Expressed in blood and 250 other tissues.
DR   ExpressionAtlas; P30511; baseline and differential.
DR   Genevisible; P30511; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0032398; C:MHC class Ib protein complex; IDA:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055038; C:recycling endosome membrane; TAS:Reactome.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:UniProtKB.
DR   GO; GO:0030881; F:beta-2-microglobulin binding; IDA:UniProtKB.
DR   GO; GO:0042605; F:peptide antigen binding; IDA:UniProtKB.
DR   GO; GO:0046978; F:TAP1 binding; IPI:UniProtKB.
DR   GO; GO:0046979; F:TAP2 binding; IPI:UniProtKB.
DR   GO; GO:0002476; P:antigen processing and presentation of endogenous peptide antigen via MHC class Ib; IDA:UniProtKB.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002477; P:antigen processing and presentation of exogenous peptide antigen via MHC class Ib; IDA:UniProtKB.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002728; P:negative regulation of natural killer cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0043322; P:negative regulation of natural killer cell degranulation; IDA:UniProtKB.
DR   GO; GO:0045953; P:negative regulation of natural killer cell mediated cytotoxicity; IDA:UniProtKB.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:UniProtKB.
DR   GO; GO:0002725; P:negative regulation of T cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0002729; P:positive regulation of natural killer cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0043323; P:positive regulation of natural killer cell degranulation; IDA:UniProtKB.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IMP:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.30.500.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR011161; MHC_I-like_Ag-recog.
DR   InterPro; IPR037055; MHC_I-like_Ag-recog_sf.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR001039; MHC_I_a_a1/a2.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00129; MHC_I; 1.
DR   PRINTS; PR01638; MHCCLASSI.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF54452; SSF54452; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   Endosome; Glycoprotein; Immunity; Lysosome; Membrane; MHC I;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..346
FT                   /note="HLA class I histocompatibility antigen, alpha chain
FT                   F"
FT                   /id="PRO_0000018884"
FT   TOPO_DOM        22..305
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        306..329
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        330..346
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          206..296
FT                   /note="Ig-like C1-type"
FT                   /evidence="ECO:0000255"
FT   REGION          22..111
FT                   /note="Alpha-1"
FT   REGION          112..203
FT                   /note="Alpha-2"
FT   REGION          204..295
FT                   /note="Alpha-3"
FT   REGION          296..305
FT                   /note="Connecting peptide"
FT   MOTIF           336..338
FT                   /note="Sorting signal sequence; Golgi-retention signal; ER-
FT                   retention signal"
FT                   /evidence="ECO:0000269|PubMed:16709803"
FT   BINDING         91
FT                   /note="Self-peptide antigen"
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   BINDING         105
FT                   /note="Self-peptide antigen"
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   BINDING         164
FT                   /note="Self-peptide antigen"
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   BINDING         168
FT                   /note="Self-peptide antigen"
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   BINDING         176
FT                   /note="Self-peptide antigen"
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   CARBOHYD        107
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        122..185
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:28636952"
FT   DISULFID        224..280
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:28636952"
FT   VAR_SEQ         204..295
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14705989"
FT                   /id="VSP_038846"
FT   VAR_SEQ         346
FT                   /note="V -> AYSVVSGNLMITWWSSLFLLGVLFQGYLGCLRSHSVLGRRKVGDMWI
FT                   LFFLWLWTSFNTAFLALQSLRFGFGFRRGRSFLLRSWHHLMKRVQIKIFD (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040349"
FT   VARIANT         13
FT                   /note="A -> V (in dbSNP:rs17875379)"
FT                   /id="VAR_056525"
FT   VARIANT         71
FT                   /note="P -> Q (in dbSNP:rs17875380)"
FT                   /id="VAR_056526"
FT   VARIANT         272
FT                   /note="P -> S (in dbSNP:rs1736924)"
FT                   /evidence="ECO:0000269|PubMed:10727083,
FT                   ECO:0000269|PubMed:14574404, ECO:0000269|PubMed:14705989,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16570139,
FT                   ECO:0000269|PubMed:1688605, ECO:0000269|PubMed:1707659,
FT                   ECO:0000269|Ref.6, ECO:0000269|Ref.7"
FT                   /id="VAR_018327"
FT   MUTAGEN         83
FT                   /note="W->R: Impairs peptide binding."
FT                   /evidence="ECO:0000269|PubMed:28636952"
FT   MUTAGEN         336..338
FT                   /note="RNR->AAA: Impairs the interaction with 14-3-3
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:16709803"
FT   MUTAGEN         336..338
FT                   /note="RNR->GKG: Impairs the anterograde ER-to-Golgi
FT                   transport."
FT                   /evidence="ECO:0000269|PubMed:16709803"
FT   MUTAGEN         346
FT                   /note="V->S: Impairs the anterograde ER-to-Golgi
FT                   transport."
FT                   /evidence="ECO:0000269|PubMed:16709803"
FT   MUTAGEN         346
FT                   /note="Missing: Impairs the interaction with coat protein
FT                   complex II; impairs the anterograde ER-to-Golgi transport."
FT                   /evidence="ECO:0000269|PubMed:16709803"
FT   STRAND          24..35
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   TURN            36..38
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          39..49
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          52..58
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          61..63
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          67..70
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           71..73
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           78..105
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          115..124
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          128..139
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          142..147
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          154..158
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           161..170
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           173..182
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           184..195
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           197..200
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          207..214
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          216..232
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          235..240
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   TURN            246..248
FT                   /evidence="ECO:0007744|PDB:5KNM"
FT   STRAND          249..251
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          258..260
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          262..271
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   HELIX           275..277
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          278..283
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          287..289
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   STRAND          291..293
FT                   /evidence="ECO:0007744|PDB:5IUE"
FT   CONFLICT        P30511-3:353
FT                   /note="N -> L (in Ref. 10; AAH09260)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   346 AA;  39062 MW;  D4782968A67E9B7D CRC64;
     MAPRSLLLLL SGALALTDTW AGSHSLRYFS TAVSRPGRGE PRYIAVEYVD DTQFLRFDSD
     AAIPRMEPRE PWVEQEGPQY WEWTTGYAKA NAQTDRVALR NLLRRYNQSE AGSHTLQGMN
     GCDMGPDGRL LRGYHQHAYD GKDYISLNED LRSWTAADTV AQITQRFYEA EEYAEEFRTY
     LEGECLELLR RYLENGKETL QRADPPKAHV AHHPISDHEA TLRCWALGFY PAEITLTWQR
     DGEEQTQDTE LVETRPAGDG TFQKWAAVVV PPGEEQRYTC HVQHEGLPQP LILRWEQSPQ
     PTIPIVGIVA GLVVLGAVVT GAVVAAVMWR KKSSDRNRGS YSQAAV
//
